3018 POSTER Treatment of Painful Bone Metastases With Magnetic Resonance Guided Focused Ultrasound

Turkevich, V.; Savelyeva, V.V.; Kanaev, S.; Dunaevsky, I.V.; Krzhivitsky, P.I.

doi:10.1016/s0959-8049(11)71091-7

Cited by 7 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The first FDA approval for a FUS device came in 1988 44 45. MRI-guided FUS device introduction in the 1990s46–49 helped in treating more than 80 000 patients, including those with symptomatic uterine fibroids,50 51 brain tumours,52 53 painful bone metastases,54 55 cancer of the prostate,56–59 pancreas60 and breast61 as well as abdominal tumours 60 62…”

Section: Focused Ultrasoundmentioning

confidence: 99%

Focused ultrasound and metrics of diffusion of disruptive medical innovation

2016

View full text Add to dashboard Cite

Innovation, as a concept in healthcare, has broad implications ranging from diagnosis to treatment of disease. The advent of new surgical modalities and medical devices continues to refine and reshape the provision of care for millions of patients across the world. Despite the tangible promise of such innovation, there remains a dearth of frameworks to understand how and how much progress has been made, particularly with regard to early-stage, non-invasive therapeutic technologies that have the potential to transform the treatment of medical disorders. A chief example of this is provided by MR-guided Focused Ultrasound. To the best of our knowledge, there are no prior reviews of the factors affecting adoption and diffusion of MRguided Focused Ultrasound as a proxy for disruptive medical technologies. The purpose of this review is to provide a comprehensive set of metrics to measure the factors affecting the rate of adoption and diffusion of these medical technologies with special focus on MR-guided Focused Ultrasound, Gamma Knife radiosurgery, and the da Vinci system. The authors review background information and literature regarding innovation in medical technology, and what constitutes disruptive innovation in the medical field. Metrics of adoption and diffusion are evaluated and applied to MR-guided Focused Ultrasound. Gamma Knife radiosurgery and the da Vinci system provide reasonable proxy technologies to understand the factors affecting the adoption and diffusion of MR-guided Focused Ultrasound. With a more comprehensive set of metrics to measure the rate of uptake and use of disruptive technology, we might move towards a better understanding of the limitations of new and potentially beneficial therapeutic modalities. OBJECTIVETo the best of our knowledge, there are no prior reviews of the factors affecting adoption and diffusion of MR-guided Focused Ultrasound as a proxy for disruptive medical technologies. The purpose of this review is to provide a comprehensive set of metrics to measure the factors affecting the rate of adoption and diffusion of these medical technologies with special focus on MR-guided Focused Ultrasound (FUS), Gamma Knife radiosurgery, and the da Vinci system. DESIGNThe authors review background information and literature regarding innovation in medical technology, and what constitutes disruptive innovation in healthcare. Metrics of adoption and diffusion of proxy innovative medical technologies are evaluated. The growth of MR-guided FUS is discussed with a new set of metrics to understand the rate of uptake and use of disruptive technology.

show abstract

Section: Focused Ultrasoundmentioning

confidence: 99%

Focused ultrasound and metrics of diffusion of disruptive medical innovation

2016

View full text Add to dashboard Cite

show abstract

“…To date, a significant amount of work has been performed using various ultrasound (US)-guided and MRI-guided systems for the treatment of symptomatic uterine fibroids [ 33 , 34 ]; brain tumors [ 35 - 37 ]; painful bone metastases [ 38 , 39 ]; prostatic [ 40 - 42 ], pancreatic [ 43 ], and breast [ 44 ] cancer; and abdominal tumors [ 45 - 47 ].…”

Section: Contentmentioning

confidence: 99%

Focused ultrasound development and clinical adoption: 2013 update on the growth of the field

et al. 2014

View full text Add to dashboard Cite

The field of therapeutic focused ultrasound, which first emerged in the 1940s, has seen significant growth, particularly over the past decade. The eventual widespread clinical adoption of this non-invasive therapeutic modality require continued progress, in a multitude of activities including technical, pre-clinical, and clinical research, regulatory approval and reimbursement, manufacturer growth, and other commercial and public sector investments into the field, all within a multi-stakeholder environment. We present here a snapshot of the field of focused ultrasound and describe how it has progressed over the past several decades. It is assessed using metrics which include quantity and breadth of academic work (presentations, publications), funding trends, manufacturer presence in the field, number of treated patients, number of indications reaching first-in-human status, and quantity and breadth of clinical indications.

show abstract

“…Preliminary clinical studies on the use of HIFU for palliation of painful bone metastases demonstrated excellent response rates and safety in heterogeneous groups of patients with painful bone metastases. 17 –19,21 –31 The aim of this study is to report our initial experience with MRgFUS for the treatment of bone metastases with respect to its efficacy in improving pain and functional scores as measured on the Brief Pain Inventory (BPI) and our preliminary analysis of urinary cytokines levels after therapy.…”

Section: Introductionmentioning

confidence: 99%

Magnetic Resonance–Guided High-Intensity-Focused Ultrasound for Palliation of Painful Skeletal Metastases: A Pilot Study

Chan

Dennis

Huang

et al. 2016

Technol Cancer Res Treat

View full text Add to dashboard Cite

Background: Bone is one of the most common sites of metastases, with bone metastases-related pain representing a significant source of morbidity among patients with cancer. Magnetic resonance-guided focused ultrasound is a noninvasive, outpatient modality with the potential for treating painful bone metastases. The aim of this study is to report our initial experience with magnetic resonance-guided focused ultrasound in the treatment of bone metastases and our preliminary analysis of urinary cytokine levels after therapy. Methods: This was a single-center pilot study of 10 patients with metastatic cancer to investigate the feasibility of magnetic resonance-guided focused ultrasound for primary pain control in device-accessible skeletal metastases. Treatments were performed on a clinical magnetic resonance-guided focused ultrasound system using a volumetric ablation technique. Primary efficacy was assessed using Brief Pain Inventory scores and morphine equivalent daily dose intake at 3 time points: before, day 14, and day 30 after the magnetic resonance-guided focused ultrasound treatment. Urine cytokines were measured 3 days before treatment and 2 days after the treatment. Results: Of the 10 patients, 8 were followed up 14 days and 6 were followed up 30 days after the treatment. At day 14, 3 patients (37.5%) exhibited partial pain response and 4 patients (50%) exhibited an indeterminate response, and at day 30 after the treatment, 5 patients (83%) exhibited partial pain response. No treatment-related adverse events were recorded. Of the urine cytokines measured, only Transforming growth factor alpha (TGFa) demonstrated an overall decrease, with a trend toward statistical significance (P ¼ .078). Conclusion: Our study corroborates magnetic resonance-guided focused ultrasound as a feasible and safe modality as a primary, palliative treatment for painful bone metastases and contributes to the limited body of literature using magnetic resonance-guided focused ultrasound for this clinical indication.

show abstract

3018 POSTER Treatment of Painful Bone Metastases With Magnetic Resonance Guided Focused Ultrasound

Cited by 7 publications

References 0 publications

Focused ultrasound and metrics of diffusion of disruptive medical innovation

Focused ultrasound and metrics of diffusion of disruptive medical innovation

Focused ultrasound development and clinical adoption: 2013 update on the growth of the field

Magnetic Resonance–Guided High-Intensity-Focused Ultrasound for Palliation of Painful Skeletal Metastases: A Pilot Study

Contact Info

Product

Resources

About